Work

Clinical value and limitations of serum CA19-9 as a biomarker of pancreatic cancer

Year: 2013
Type: article
Abstract: Timely diagnosis and effective treatment of pancreatic cancer remains a distinct clinical challenge. Serum carbohydrate antigen (CA19-9) has emerged as a promising biomarker of pancreatic tumors and clinical studies have indicated its potential benefit in diagnosis, prognosis, and management of the disease. Compared with other biomarkers, serum CA19-9 shows better sensitivity and specificity for diagnosis of pancreatic cancer, but many limitations exist. Besides general instances of false-positive results, serum CA19-9 is associated with a high rate of false-negative results for patients with the Lewis-negative phenotype. Therefore, while serum CA19-9 may be a clinically valuable biomarker of pancreatic cancer, its results should be confirmed with imaging and histological findings.
Author: Fan Yanhu
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W2356883306
FWCI:
Cites:
Cited by:
Related to: 10